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SAMUEL A. SCHIFF,3 AND PATRICIA P. KATZ6
Objective. Individuals with systemic lupus erythematosus (SLE) often experience symptoms that affect family relation-
ships, which are important components of quality of life. To assess the impact of SLE on family role functioning, we
developed a 6-domain (Fatigue, Activity participation, Mental health, Isolation, Love and intimacy, and You/fulﬁlling
family roles [FAMILY]) measure. The objectives of this study were to pilot test and achieve preliminary validation for the
SLE-FAMILY questionnaire.
Methods. This was a 3-phase study. In phase 1 (development), domains were identiﬁed and items were generated for
evaluation. During phase 2 (pilot test), a pilot test was conducted to assess the performance of candidate items. In phase
3 (initial validation), 52 individuals with SLE completed questionnaires, including the 6-item SLE-FAMILY. Data were
analyzed for internal consistency reliability, and validity was assessed using correlations between the SLE-FAMILY
questionnaire and well-validated measures.
Results. The SLE-FAMILY had good test–retest reliability (0.82) and internal consistency (0.67). Reliability analysis of
individual items revealed weakness in the performance of item 5. We reviewed raw data and determined that 9
individuals likely overlooked the reverse scoring of item 5, thus explaining its poor reliability. When these 9 individuals
were excluded from analysis, Cronbach’s alpha increased to 0.71, while test–retest reliability remained acceptable (0.75).
Spearman’s rho correlations supported the validity of the SLE-FAMILY measure. A pilot test of the SLE-FAMILY
questionnaire without the reverse-scored item was conducted; results suggested that the modiﬁed version is superior to
the initial form.
Conclusion. The SLE-FAMILY questionnaire is a promising new instrument for robust measurement of family role
functioning.
INTRODUCTION
Individuals with systemic lupus erythematosus (SLE) of-
ten contend with fatigue (1,2), pain (3), sleep disturbances
(2,4), depression (1,3,5), and anxiety (6,7). Given the un-
predictability of SLE, the severity of symptoms, and the
fact that it affects young adults (8,9), a diminished ability
to fulﬁll social roles within the family is expected; how-
ever, the extent of this social role disruption and potential
impact on disease outcomes and psychological well-being
may not be fully appreciated.
The few studies that have been conducted have shown
that individuals with SLE greatly value their relationships
with family and friends, but many report periodic or per-
manent effects of the disease on their daily activities at
home and at work (10,11). Interference with daily activi-
ties due to impaired physical and psychological function-
ing can lead to social role dysfunction, i.e., the impaired
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ability to fulﬁll key social roles such as spouse, parent, and
worker. Social role dysfunction is thought to be central to
impaired quality of life and has been found to mediate the
relationship between SLE disease severity and psycholog-
ical functioning (12).
Disruption of positive family relationships may be par-
ticularly problematic for people with SLE. In a study com-
paring individuals with SLE to those with rheumatoid
arthritis, issues related to home and living environment
were rated as more important by people with SLE (13). The
high importance placed on family life by those with SLE
may arise from an increased presence of young children in
the home. SLE strikes primarily women of childbearing
age and, compared to 20 years ago, there is far less concern
about the risks to both mother and unborn child. There-
fore, many with SLE strive to have a “normal” and fulﬁll-
ing family life, but they may encounter multiple barriers
due to the effects of the disease.
Understanding social role functioning within the family
has not been well studied in SLE. This may be due in part
to the fact that there is a lack of instruments that tap into
this speciﬁc area. Given the importance of family to indi-
viduals with SLE and the key role of social support, it
seems appropriate that such an instrument be developed.
Therefore, in accordance with the objectives of this study
to develop, pilot test, and achieve preliminary validation
for a new measure, we developed the SLE-FAMILY (Fa-
tigue, Activity participation, Mental health, Isolation,
Love and intimacy, and You/fulﬁlling family roles) ques-
tionnaire to assess the impact of SLE on family role func-
tioning.
PATIENTS AND METHODS
Study design. This study was conducted in 3 phases
plus a small trial to assess the performance of a slightly
modiﬁed version of the instrument. Phase 1 consisted of a
literature review, a qualitative study, selection of domains
to be associated with the SLE-FAMILY measure, and gen-
eration of items. During phase 2, a pilot test was conducted
to assess performance of candidate items, as well as read-
ability and comprehension of items and instructions.
Based on these ﬁndings and patient feedback, the SLE-
FAMILY measure was reﬁned and ﬁnalized. Phase 3 con-
sisted of a validity trial where the SLE-FAMILY question-
naire and validated measures were administered to 52 SLE
patients. One week later patients completed the SLE-
FAMILY questionnaire a second time to evaluate test–
retest reliability. Seven of the 52 patients completed cog-
nitive interviews. Upon completion of phase 3, a small
trial to assess the performance of a slightly modiﬁed ver-
sion of the instrument was conducted.
Phase 1: instrument development. Participants. Twenty
patients from the rheumatology clinic of the University of
Medicine and Dentistry of New Jersey-Robert Wood John-
son Medical School (UMDNJ-RWJMS) completed qualita-
tive interviews. All participants met American College of
Rheumatology (ACR) criteria for SLE (14), were between
ages 20 and 65 years, and were ﬂuent in English. This
study was approved by the Institutional Review Board at
UMDNJ-RWJMS. All participants completed a consent
form and received a $30 subject fee. No patient could
participate in more than one phase of this study. Demo-
graphic information appears in Table 1.
Signiﬁcance & Innovations
● Systemic lupus erythematosus (SLE) tends to
strike individuals during childbearing years;
therefore, the impact on family role functioning
can be particularly profound and stressful for all
involved.
● Existing measures of quality of life often do not tap
into the unique aspects of family role functioning
in most disease states.
● The SLE-FAMILY is a brief self-report question-
naire that provides a more granular assessment of
family role functioning in the context of the
unique concerns of individuals with SLE.
Table 1. Characteristics of samples from all 3 study phases and the followup pilot study*
Phase 1:
interviews
(n  20)
Phase 2:
pilot study
(n  25)
Phase 3:
validation
(n  52)
Followup
pilot
(n  15)
Female, % (no.) 90.0 (18) 96.0 (24) 88.5 (46) 88.1 (59)
Age, mean  SD years 38.0  11.5 39.1  11.6 36.8  11.9 38.9  12.6
White non-Hispanic, % (no.) 60.0 (12) 29.2 (7) 33.3 (17) 34.8 (23)
Married, % (no.) 50.0 (10) 43.5 (10) 34.6 (18) 38.8 (26)
Duration of SLE, mean  SD years 10.3  7.2 7.8  5.2 8.4  6.7 8.4  6.3
SLE 2 years, % (no.) 25.0 (5) 14.3 (3) 24.5 (12) 13.3 (2)
SLAQ score, mean  SD – 16.9  8.7 13.6  9.2 –
Mild disease activity, % (no.) (SLAQ score 4
[1 SD below the mean])
– 24.0 (6) 19.2 (10) –
Severe disease activity, % (no.) (SLAQ score 22
[1 SD above the mean])
– 20.0 (5) 17.3 (9) –
* SLE  systemic lupus erythematosus; SLAQ  Systemic Lupus Activity Questionnaire.
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Procedures. Based on an extensive review of the litera-
ture regarding SLE and study team expertise, a brief inter-
view was developed and administered to 20 patients with
SLE to identify themes or domains anticipated to play a
role in health-related family role functioning. The inter-
views were brief (10 minutes) and responses were noted
verbatim. Interviewers (DCR and SVS) clariﬁed the content
of responses with patients when uncertain and were al-
lowed to show them their notes for veriﬁcation. The notes
were transcribed and the 20 transcripts were indepen-
dently scored by 2 expert raters (ALH and DCR). The two
raters coded the content of the interviews by using a priori
codes for themes and then using grounded coding to allow
unidentiﬁed themes to emerge. The themes or domains
were then coded based on the frequency of report and
emphasis placed on the topic by patients. Highly empha-
sized content was denoted by an asterisk. Following these
interviews, 2 of the SLE patients were invited to become
members of the study team. Both individuals, one white
man and one African American woman, were in their
mid-30s and both were married with young children in the
home. The patient advisors joined the study team on all
conference calls in order to provide feedback in regard to
the patient perspective throughout the course of instru-
ment development, including identifying the themes or
domains, item generation and evaluation, and ﬁnalizing
the content and appearance of the SLE-FAMILY instru-
ment.
Next, the study team generated several items for each of
the 6 top priority domains and reﬁned the most favored
ones. Response options were established, instructions
were drafted, and responses, instructions, and items were
subjected to Flesch-Kincaid Grade Level readability tests
to meet the goal of having content at no higher than an
eighth-grade reading level. The instructions were crafted
to intimate that “family” can be interpreted broadly, as it
became clear during the course of the interviews that fam-
ily can mean different things to different people. The in-
strument was formatted to use a 7-point numerical rating
scale to indicate to what degree an item is true of the
respondent at that time. The SLE-FAMILY pilot question-
naire consisted of 16 items, i.e., 2 or 3 items for each of the
6 domains.
Phase 2: pilot testing and instrument reﬁnement. Par-
ticipants. Twenty-ﬁve patients from the UMDNJ-RWJMS
rheumatology clinic participated in the pilot trial. Consis-
tent with phase 1, all participants met the ACR criteria for
SLE (14), were between ages 20 and 65 years, were ﬂuent
in English, completed a consent form, and received a $30
subject fee. Their demographic information appears in
Table 1.
Procedures. Participants completed a series of ques-
tionnaires including the 16-item SLE-FAMILY pilot ques-
tionnaire and a demographics form. The order of the
questionnaires varied for each patient, although the SLE-
FAMILY always appeared ﬁrst. Patients were directed
to read the instructions associated with the question-
naires, but no other explanations about completing them
were offered. Patients were allowed to ask questions if the
instructions were unclear. Inquiries related to the SLE-
FAMILY measure were recorded to advise later edits to the
questionnaire.
Phase 2 measures. In order to assess the performance of
the items, the following well-validated measures were
used.
Systemic Lupus Activity Questionnaire (SLAQ). The
SLAQ is a self-report measure of disease activity (15). It
contains 24 items related to disease activity in SLE (e.g.,
malar rash, fatigue, photosensitivity, and chest pain), as
well as an item querying ﬂares in the last 3 months and a
numerical rating scale of disease activity. Scores range
from 0–44.
Medical Outcomes Study Short Form 36 (SF-36). The
SF-36 provides a physical composite summary score and a
mental composite summary (MCS) score and addresses 8
health domains: 1) physical functioning, 2) role function-
ing, 3) bodily pain, 4) general health, 5) social functioning,
6) role and emotional functioning, 7) vitality (energy ver-
sus fatigue), and 8) general mental health (16,17).
Sheehan Disability Scale (SDS). The SDS is a 5-item
self-report instrument for the assessment of disability in 3
key areas (work/school, social life, and family life/home
responsibilities), and 2 questions query days of missed
work/school and days of feeling less productive (18).
Fatigue Severity Scale (FSS). The 9-item FSS is a self-
report measure of fatigue severity, originally developed
and validated for SLE and multiple sclerosis patient pop-
ulations (19). Scores range from 1 (no fatigue) to 7 (severe
fatigue). Scores 3 indicate that patients are experienc-
ing fatigue, while scores 4 suggest that the fatigue is
severe. The FSS has demonstrated good test–retest reli-
ability, internal consistency, validity, and sensitivity to
clinical change (19).
Satisfaction with Life Scale (SWLS). The SWLS is a
5-item self-report measure of global life satisfaction previ-
ously found to be valid and reliable (20,21). Scores 20
reﬂect levels of life satisfaction that are slightly below
average, while scores 29 are associated with people who
are very highly satisﬁed with their lives.
Positive and Negative Affect Scale (PANAS). The PANAS
consists of 2 mood scales with 10 items each for the as-
sessment of positive and negative affect. The scales have
been shown to be internally consistent, uncorrelated, and
stable over a 2-month period; good convergent and dis-
criminant validity have also been demonstrated (22).
Multidimensional Scale of Perceived Social Support
(MSPSS). The MSPSS is a 12-item questionnaire validated
for the assessment of perceived social support (23). Re-
spondents indicate to what degree they agree or disagree
with statements like, “My family really tries to help me.” A
single global scale can be calculated, as well as 3 subscale
scores for perceived social support from friends, family,
and signiﬁcant others.
Phase 2 analysis. Data were analyzed by grouping items
by domain, with Cronbach’s alpha calculated for each
domain. Items for which the domain’s alpha increased
when they were dropped from the domain were elimi-
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nated. Correlations for the remaining items and reference
scales, both general and those speciﬁc to each domain,
were used as a basis to select 1 item from each domain.
Judgment regarding the ﬁnal items included in the SLE-
FAMILY questionnaire combined statistical analysis with
the consensus of the development team, including the
patient advisors.
Phase 3: assessment of validity and reliability. Partici-
pants. Fifty-two patients were recruited from the UMDNJ-
RWJMS rheumatology clinic to participate in the validity
study. As in the other phases, participants met the ACR
criteria for SLE, were between ages 20 and 65 years, were
ﬂuent in English, completed a consent form, and received
a $30 subject fee. Demographic information is presented in
Table 1.
Procedures. Patients completed the same question-
naires used in phase 2. The questionnaires appeared in
random order, although the SLE-FAMILY questionnaire
always appeared ﬁrst. Patients were instructed to read the
directions associated with the questionnaires, but no other
explanations about completing the questionnaires were
offered. Seven of the phase 3 patients participated in a
debrieﬁng and face validity trial. Upon completion of the
questionnaires, each consecutive patient was invited to
participate in the interview until 7 patients were recruited.
The semistructured interview consisted of questions that
covered various topics, including the clarity of the instruc-
tions, item clarity, response options, and suggestions for
other pertinent items. Also included were questions re-
lated to face validity for each of the 6 items. These patients
received another $20 for their additional participation.
One week later all 52 respondents were asked to com-
plete the SLE-FAMILY questionnaire a second time in
order to assess test–retest reliability. This followup SLE-
FAMILY questionnaire was collected by mail. Those who
did not return the followup questionnaire in a timely
manner received a phone call reminder. Participants who
completed the followup SLE-FAMILY questionnaire were
paid an additional $20 fee for their participation.
Phase 3 measures. The 6-item version of the SLE-
FAMILY was used. This 6-item instrument has a single
item to represent each of the 6 domains presumed to be
associated with health-related family role functioning
(Table 2). Responses are registered on a 7-point Likert
scale anchored by phrases such as, “No limitations on my
ability,” “Some limitations on my ability,” and “Com-
pletely limited my ability.” A total score is achieved by
summing the responses and dividing by the number of
items with a response. Scores range from 1–7, with higher
scores indicating worse family role functioning.
In order to assess the performance of the questionnaire,
the same well-validated measures used in phase 2 were
used in phase 3 as well (SF-36, SDS, FSS, PANAS, SWLS,
and MSPSS). The same demographics form was also used.
Phase 3 analysis. Cronbach’s alpha was used to assess
internal consistency. Unidimensionality was assessed us-
ing an exploratory bifactor model, which features a com-
parison of a single factor model to a model with a general
factor and group factors (24). Test–retest reliability was
assessed using the intraclass correlation form (2,1) (25) of
the total SLE-FAMILY scores from the 2 administrations.
Item statistics were calculated to assess the correlations
between individual items and the total score on the SLE-
FAMILY questionnaire, while also correcting for item
overlap and scale reliability by subtracting the item vari-
ance and replacing it with the estimated common variance
(26). Construct validity of the SLE-FAMILY questionnaire
was assessed via Spearman’s rank correlations with the
other measures.
RESULTS
Phase 1 results. Participants consisted of 18 women and
2 men. Most reported moderate to high work and social life
disability and moderate disruption in family and home
life. The meaning of “family” varied as follows: 95% of
patients listed immediate family members as their family,
but 70% also included extended family, friends, and/or
even pets. Most patients (60%) indicated that their lives
were out of balance due to SLE and that work and other
mandatory obligations often had to come before family.
Similarly, 80% reported that SLE negatively impacted
their ability to function properly in various family roles
(e.g., mother/father, husband/wife, or “bread winner”).
The most common themes or domains and their sub-
themes were: 1) fatigue: when asked about the most both-
ersome symptom of SLE, fatigue was most frequently vol-
unteered (65%, n  13) and was reported as problematic
by 90% of SLE patients interviewed. Fatigue, even more so
than pain, was cited as a major reason for not being able to
participate in family activities; 2) family activity partici-
pation: 55% reported that ﬂares were unpredictable, but in
Table 2. Reliability analysis of individual items
(n  52)*
Items
SLE-FAMILY
total
1. Fatigue got in the way of the things
that I needed to do for my family.
0.76
2. My SLE has been hard on my
family emotionally.
0.63
3. My family excluded me from things
because of my SLE.
0.69
4. My SLE got in the way of my
developing or maintaining intimate
relationships.
0.70
5. My SLE limited my ability to do all
the things I wanted to do with my
family.
0.22
6. Despite my SLE I was able to fulﬁll
my family roles.
0.59
* Values show the correlations between individual items and the
total score on the SLE-FAMILY corrected for item overlap and scale
reliability by subtracting the item variance and replacing it with the
estimated common variance. SLE  systemic lupus erythematosus;
FAMILY  Fatigue, Activity participation, Mental health, Isolation,
Love and intimacy, and You/fulﬁlling family roles.
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contrast to what we anticipated, most patients learned
how to cope with them. Instead of having concerns about
planning ahead due to the unpredictability of the disease,
“active” activities (especially outdoor activities requiring
exposure to the sun or vigorous exercise) were reportedly
greatly affected by SLE; 3) mental health: 88% reported
that poor mental health impaired their ability to do the
things that they liked to do with their families but, more
importantly, the mental health and well-being of their
entire family was affected by their SLE; 4) isolation versus
social support: withdrawal tended to occur during disease
ﬂares when patients commonly noted that they would
retreat to bed. However, feeling excluded by loved ones
from valued activities and isolated by others was deemed
more distressing; 5) intimacy and love: of the 19 sexually
active participants, 84% reported that SLE had a negative
impact on their ability to have a gratifying sex life. Close to
half reported that this distanced them from their signiﬁ-
cant others; and 6) role functioning: 80% described ways
in which family roles, especially those of spouse and par-
ent, were adversely impacted by SLE.
Phase 2 results. Data from the 25 patients completing
the SLE-FAMILY pilot questionnaire showed that 9 of the
16 items could be considered “strong” in that they con-
tributed signiﬁcantly to domain alpha and were highly
correlated with the total SLE-FAMILY score based on all
16 items, as well as the SDS family subscale (Table 3). A
single item for each of the 6 domains was selected based
on those correlations and associations with measures of a
similar construct from the validated instruments. More
speciﬁcally, the fatigue item chosen had the strongest cor-
relations with the SLAQ fatigue item and the FSS. The
activities item selected was highly correlated with SF-36
social functioning and MSPSS family. The mental health
item had the highest correlations with the SF-36 MCS and
the SF-36 mental health domain. The strongest isolation
item had the highest correlation with the SDS family, SDS
social, the SWLS, and SF-36 role emotional. The love/loss
of intimacy item was strongly correlated with SF-36 social
functioning, SF-36 role emotional, and the SWLS. The
you/social role item selected had a high correlation with
SF-36 social role functioning and SDS family. The 6 cho-
sen items combined as a single questionnaire had good
internal consistency (  0.88) and were highly correlated
with SDS family item (r  0.89) and SF-36 social function-
ing (r  0.88).
Phase 3 results. Data from the 52 patients with SLE
completing this phase showed that the SLE-FAMILY ques-
tionnaire had good test–retest reliability (0.82) and in-
ternal consistency (0.67). However, reliability analysis of
individual items revealed a weakness in the performance
of item 5 (Table 2). After reviewing the raw data, it ap-
peared that 9 patients had likely overlooked the reverse
direction of responses for item 5 (i.e., for all other items the
response scale was shown with the most positive response
on the far left and the most negative response on the far
right. For item 5, the positive response was on the right
and the negative on the left), therefore explaining its poor
reliability. When the 9 patients were excluded from the
analysis, alpha increased to 0.71, while test–retest reliabil-
ity remained acceptable (0.75). Results from the assess-
ment of unidimensionality using bifactor analysis and
omitting participants with aberrant responses to item 5
showed that loadings for the general factor in the bifactor
model shrank somewhat compared to the single factor
model (a phenomenon previously observed) (24), but no
variable’s loading shrank by more than 16%. With just 6
items, 1 per domain, there could only be limited evidence
for or against unidimensionality. Together, however, these
results do not indicate any gross violation of unidimen-
sionality.
Table 3. Individual item correlations with 6-item SLE-FAMILY total score and the family subscale of the
Sheehan Disability Scale (SDS)*
Items
SLE-FAMILY
total
SDS-family
subscale
1. Because of my SLE I frequently missed important family activities. 0.72 0.64
2. Fatigue got in the way of the things that I needed to do for my family. 0.78 0.75
3. Concerns that I might have a disease ﬂare made it difﬁcult to plan family activities. 0.23 0.05
4. My family excluded me from things because of my SLE. 0.76 0.66
5. I felt like a burden to my family because of my SLE. 0.67 0.38
6. My SLE got in the way of my developing or maintaining intimate relationships. 0.83 0.76
7. My SLE limited my ability to do all the things I wanted to do with my family. 0.71 0.77
8. My SLE has been hard on my family emotionally. 0.77 0.69
9. Fatigue made it difﬁcult for me to do all the family activities that I would like to do. 0.79 0.52
10. I felt that I was not able to contribute adequately to my family. 0.74 0.56
11. I felt isolated from my family because of my SLE. 0.56 0.33
12. My SLE caused me to feel less emotionally connected to my family members. 0.50 0.20
13. If I had less fatigue, I could have done so much more for and with my family. 0.75 0.70
14. My SLE got in the way of my having a gratifying sex life. 0.47 0.38
15. It troubled me that my family worried about my health and well-being. 0.58 0.66
16. Despite my SLE, I was able to fulﬁll my family roles. 0.75 0.64
* See Table 2 for deﬁnitions.
Preliminary Validation of the SLE-FAMILY Questionnaire 1345
Spearman’s rho correlations supported the validity of
the SLE-FAMILY measure as its total score was signiﬁ-
cantly related to SDS family (r  0.67, P  0.001) and SDS
social (r  0.60, P  0.001); MSPSS family (r  0.33, P 
0.031); PANAS negative subscale (r  0.55, P  0.001);
FSS (r  0.62, P  0.001); and the SLAQ (r  0.68, P 
0.001). Similarly, the SLE-FAMILY total score was in-
versely related to relevant SF-36 subscales scores, includ-
ing social functioning (r  0.55, P  0.001); role emo-
tional (r0.42, P 0.005); role physical (r0.59, P
0.001); and mental health (r  0.48, P  0.001). Table 4
shows the mean  SD, as well as the correlations for the
SLE-FAMILY measure and other measures omitting the
participants with aberrant responses to item 5 (n  43).
Patients taking part in the cognitive interviews (n  7)
indicated that the instructions were easy to read and
readily understandable. Also, 90% of the time, the 6
items were rated as 9 or 10 on a 10-point scale, where
10 represented an “excellent” item for the assessment of
a particular domain. Moreover, in the comments sec-
tion, every patient expressed the view that evaluating
how SLE affected family role functioning was extremely
important.
Followup pilot for the revised SLE-FAMILY measure.
In the original sample, inspection of individual responses
suggested that some respondents may have overlooked the
reverse scoring pattern of item 5. Therefore, we conducted
a small followup study to evaluate a version of the SLE-
FAMILY questionnaire with item 5 scored in the same
direction as the other items. Fifteen patients meeting the
same recruitment criteria were recruited from the UMDNJ-
RWJMS rheumatology clinic. Demographic information is
presented in Table 1. Patients gave informed consent then
completed the revised version of the SLE-FAMILY ques-
tionnaire (Supplemental Appendix A, available in the on-
line version of this article at http://onlinelibrary.wiley.
com/journal/10.1002/(ISSN)2151-4658). In this sample,
which was given the nonreversed version of item 5, the
individual patterns of scores were consistent across all
items. The total of the other items was a reasonable pre-
dictor of the item 5 response (r2  0.61) and the standard-
ized alpha dropped slightly from 0.90 to 0.87 when item 5
was dropped. These results support our belief that some
individuals overlooked the reverse scoring of item 5 and
suggest that no reverse scoring gives better results on this
instrument.
Table 4. Phase 3 results for the SLE-FAMILY measure and other measures omitting the
participants with aberrant responding to item 5 (n  43)*
Measure Mean  SD
Correlation
predicted
Correlation
observed
SLE-FAMILY total 3.5  1.0 – –
Fatigue (item 1) 4.4  1.2 – –
Activity participation (item 5) 4.1  1.7 – –
Mental health of entire family (item 2) 4.1  1.8 – –
Isolation (item 3) 2.2  1.6 – –
Love and intimacy (item 4) 3.2  2.1 – –
You/family role functioning (item 6) 3.5  1.5 – –
SLAQ total disease activity score 15.8  8.5  0.676†
SDS family life/home responsibilities 5.5  2.8  0.670†
SDS social life 5.7  3.0  0.598†
MSPSS social support from family 5.9  1.5 – 0.330‡
Satisfaction With Life Scale 20.7  7.7 – 0.311‡
Fatigue Severity Scale 5.0  1.3  0.0618†
PANAS positive affect 33.8  6.4 – 0.199
PANAS negative affect 21.6  7.3  0.549†
Short Form 36 scores
Physical component summary 49.1  19.7 – 0.570†
Mental component summary 53.9  18.0 – 0.549†
Physical functioning 53.6  26.5 – 0.550†
Role-physical 42.4  43.9 – 0.591†
Bodily pain 52.9  29.1 – 0.431†
General health 43.2  22.9 – 0.418†
Vitality 44.7  20.2 – 0.343‡
Social functioning 57.0  28.9 – 0.549†
Role-emotional 50.4  47.9 – 0.416†
Mental health 64.9  20.5 – 0.479†
* Correlations are for the SLE-FAMILY questionnaire total and other measures. SLAQ  Systemic Lupus
Activity Questionnaire; SDS  Sheehan Disability Scale; MSPSS Multidimensional Scale of Perceived
Social Support; PANAS  Positive and Negative Affect Scale (see Table 2 for additional deﬁnitions).
† Correlation is signiﬁcant at the 0.01 level (2-tailed).
‡ Correlation is signiﬁcant at the 0.05 level (2-tailed).
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DISCUSSION
The SLE-FAMILY questionnaire is a promising new in-
strument for the measurement of an important area of
health-related quality of life, family role functioning. In
the preliminary validation study, the 6-item SLE-FAMILY
measure demonstrated good reliability and validity. A
modiﬁcation made to one of the items, changing the scor-
ing direction to make it uniform with the other 5 items,
was shown to further enhance the performance of the
instrument. Each item on the SLE-FAMILY questionnaire
was designed to give insight into 6 domains related to
family role functioning: fatigue, activity participation,
mental health, isolation, love and intimacy, and “you”
(family role fulﬁllment). The total score provides a com-
posite score based on these domains that relates to the
construct of interest, the impact of SLE on family role
functioning. We found that no other measure had a score
with a stronger association with patient-assessed disease
activity than did the SLE-FAMILY measure. The measure
was also highly associated with self-report physical and
mental health, satisfaction with life, and symptom sever-
ity. Although the SLE-FAMILY measure had a strong cor-
relation with the SDS family scale supportive of its valid-
ity, it explained only 45% of the variation in the SDS
family scale, suggesting the SLE-FAMILY measures some-
thing unique. Family role functioning could be a valuable
and sensitive measure of key outcomes in SLE for a num-
ber of reasons.
Qualitative interviews conducted as part of this project
highlighted the importance that individuals with SLE
placed on their family relationships. People with SLE in-
dicated that these relationships and their ability to func-
tion in the roles of spouse and parent were critical and
often adversely impacted by SLE. Sixty percent reported
that their lives were out of balance because SLE often
forced them to choose work and other mandatory activities
over family. Similarly, 80% reported that their ability to
function properly in various family roles (e.g., mother/
father, husband/wife, or “bread winner”) is negatively af-
fected by SLE. It seems that symptoms like pain and fa-
tigue limit the resources available for functioning overall,
and family activities such as going to a movie or attending
a child’s sporting event were foregone in order to address
work-related demands and/or household chores. It has
been previously shown in SLE that these valued life activ-
ities, which are central to good quality of life, can stop
being a priority (27).
We also learned that the deﬁnition of family is highly
individualized and can include others outside of the nu-
clear family (e.g., in-laws from a previous marriage,
friends, and pets) whose relationships are highly valued
and presumed to be affected by the patient’s SLE. A con-
sistent theme was how the symptoms of SLE, especially
fatigue and sun sensitivity, interfered with the outdoor
activities that patients most wanted to participate in with
their families. Loss of participation in these and other
activities was viewed as affecting the mental health of both
patients and family members. Depression is common in
SLE (1,3) and has been directly correlated with disease
activity (6) and functional disability (1). It is unclear
whether the increased rates of mood disorders in individ-
uals are due to changes secondary to SLE, the result of
persistent stress that stems from living with a chronic
disease, and/or due to some other process (1,3,7). None-
theless, the mental health and general well-being of many
SLE patients and their families are compromised, and this
can negatively affect these essential relationships.
The SLE-FAMILY measure assesses functioning in a
unique but critical area, upon which individuals with
the disease place a high value. While further validation
studies remain to be conducted, we suggest that family
role functioning, as measured by the SLE-FAMILY ques-
tionnaire, may prove to play an important role in over-
all psychological well-being among individuals with SLE.
Further, such an instrument would likely prove to be a
valid measure in many chronic disease conditions. While
the SLE-FAMILY measure (Supplemental Appendix A,
available in the online version of this article at http://online
library.wiley.com/journal/10.1002/(ISSN)2151-4658) was
developed for those with SLE, the same instrument may
require minimal or no revision for evaluating family-
speciﬁc concerns in other populations.
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